ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2058

Organ-specific disease activity and serological patterns in idiopathic inflammatory myopathies: A descriptive study in a Hispanic cohort
Abstract Number: 0439

Osteoarthritis and Other Degenerative Musculoskeletal Disorders Are Common and Often Associated with Active Inflammation in Difficult-to-Treat Rheumatoid Arthritis: A Cross-Sectional Cohort
Abstract Number: 1509

Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study
Abstract Number: 0140

Outcome Of Patients With Non-Criteria Manifestations Of Primary Antiphospholipid Syndrome Treated With Immunosuppressants -A Single Centre Study
Abstract Number: 0411

Outcomes in Juvenile Idiopathic Arthritis Based on Geographic Region in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
Abstract Number: 0416

Outcomes Of Children with Juvenile Idiopathic Arthritis Receiving Biological Disease-Modifying Anti-Rheumatic Drugs: Retrospective Analysis of A Real-World Experience From A Resource-Limited Setting
Abstract Number: 1522

Outcomes of Continuing Hydroxychloroquine following Renal Transplant in Patients with Lupus Nephritis: A retrospective Cohort Study using the TrinetX database
Abstract Number: 0492

Outcomes of Total Knee Replacement in Patients with Rheumatoid Arthritis: A National Inpatient Sample Database Analysis
Abstract Number: 1706

Overcoming Barriers to ANA Testing in Pediatric Populations in Africa
Abstract Number: 1271

Overcoming Obstacles to Care: Survey of Adult Patients with Idiopathic Inflammatory Myopathies (IIM)
Abstract Number: 1206

Overexpression of lymphotoxin in autophagy-deficient mice as model for inclusion body myositis
Abstract Number: 1221

Oxytocin pathway gene BST1 polymorphism rs4273468 genotype GG is negatively associated with Fibromyalgia
Abstract Number: 1244

PACFiND: Co-Designing Principles To Inform Reconfiguration Of Fibromyalgia Care Across Health Systems
Abstract Number: 0397

Paediatric uveitis – Retrospective comparison of cataract surgery outcomes with or without intraocular lens implantation from two tertiary centres in United Kingdom
Abstract Number: 2104

Pain 0-10 visual analog scale (VAS) and RAPID3 (routine assessment of patient index data) in OA and RA are similar in 2024 to 1979 and 1989

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].